The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe

Rapid infusion (RI) of the rituximab biosimilar CT‐P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT‐P10 and reference rituximab are known to be frequently administered using a RI regimen (≤90 min) in clinical practice, published data on...

Descripción completa

Detalles Bibliográficos
Autores principales: Bishton, Mark, Marshall, Scott, Harchowal, Jatinder, Salles, Gilles, Golfier, Camille, Tucci, Alessandra, Fernández, Alicia Rodriguez, Sanchez Blanco, Jose Javier, Bocchia, Monica, Kim, SooKyoung, Lee, Young Nam, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545983/
https://www.ncbi.nlm.nih.gov/pubmed/35168291
http://dx.doi.org/10.1002/hon.2978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545983/
https://www.ncbi.nlm.nih.gov/pubmed/35168291
http://dx.doi.org/10.1002/hon.2978

Ejemplares similares